Grifols (GRFS) Cash from Operations Growth (3y) (2013 - 2020)
Grifols (GRFS) Cash from Operations Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 18.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.88% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 15.19% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -9.10% |
| Dec 31, 2019 | 24.45% |
| Dec 31, 2018 | 11.10% |
| Jun 30, 2018 | -8.83% |
| Mar 31, 2018 | 43.48% |
| Dec 31, 2017 | 41.29% |
| Jun 30, 2017 | 51.85% |
| Mar 31, 2017 | -3.27% |
| Dec 31, 2016 | -14.17% |
| Sep 30, 2016 | 26.64% |
| Dec 31, 2015 | 18.18% |
| Sep 30, 2015 | 5.26% |
| Jun 30, 2015 | -3.65% |
| Mar 31, 2015 | 616.89% |
| Dec 31, 2014 | -79.81% |
| Sep 30, 2014 | 140.41% |
| Jun 30, 2014 | -63.92% |
| Mar 31, 2014 | 42.06% |
| Dec 31, 2013 | 91.29% |
| Sep 30, 2013 | 55.40% |